Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study

Abstract Idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Leveraging an international multicenter RRMM cohort, we compared the outcome of ide‐cel (n = 162)...

Full description

Bibliographic Details
Main Authors: Maximilian Merz, Anca‐Maria Albici, Bastian vonTresckow, Kristin Rathje, Roland Fenk, Tobias Holderried, Fabian Müller, Natalia Tovar, Aina Oliver‐Cáldes, Vladan Vucinic, Soraya Kharboutli, Ben‐Niklas Bärmann, Francis Ayuk, Uwe Platzbecker, Friedrich Stölzel, Nathalie Schub, Friederike Schmitz, David Fandrei, Patrick Born, Cyrus Khandanpour, Christine Hanoun, Keven Hörster, Marcel Teichert, Barbara Jeker, Michele Hoffmann, Nicolaus Kröger, Carlos Fernández de Larrea, Thomas Pabst, Nico Gagelmann
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:HemaSphere
Online Access:https://doi.org/10.1002/hem3.70070

Internet

https://doi.org/10.1002/hem3.70070

Similar Items